[Skip to Content]
[Skip to Content Landing]
Views 2,047
Citations 0
From The Medical Letter on Drugs and Therapeutics
November 5, 2019

Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

JAMA. 2019;322(17):1709-1710. doi:10.1001/jama.2019.16482

Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.1

CABP is a leading cause of hospitalization and death in adults, especially the elderly.2 Causative bacterial pathogens include Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Chlamydophila pneumoniae, and Legionella species.